Table 1 Patient demographics

Age at first linaclotide dose, mean (SD)

Female sex, % (n)

White race, % (n)

SSc type: Diffuse cutaneous disease, % (n)

Disease duration in years, RP or non-RP, median (IQR)

Medsger GI score at initiation of linaclotide, % (n)

 0 (Normal)

 1 (Requiring medications for reflux or abnormal small bowel series)

 2 (High-dose reflux medications or antibiotics for bacterial overgrowth)

 3 (Malabsorption syndrome or episodes of pseudo-obstruction)

 4 (Requiring total parental nutrition)

Sicca symptoms, % (n)

Myopathy, % (n)

Cardiac involvement (Medsger ≥ 1), % (n)

Lung involvement (Medsger > 1), % (n)

Raynaud’s (Medsger ≥ 2), % (n)

Antibody status

 Anti-Scl-70 antibodies, % (n)

 Anti-CENP antibodies, % (n)

 Anti-RNA pol-3 antibodies, % (n)

 Anti-U3RNP antibodies, % (n)

UCLA GIT 2.0 constipation score, mean (SD) n = 9

Whole gut scintigraphy data

 Abnormal large bowel transit at 72 h, % (n)

 Percent large bowel emptying at 72 h, median (IQR)

Medications used prior to linaclotide

 Polyethylene glycol, % (n)

 Senna, % (n)

 Oral docusate, % (n)

 Docusate suppository, % (n)

 Tegaserod, % (n)

 Lubiprostone, % (n)

 Pyridostigmine, % (n)

 Prucalopride, % (n)